IPSEY Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 20:11):

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases...

Stats
Dagens volum	479.00
Gjennomsnittsvolum	1 524.00
Markedsverdi	9.94B
Last Dividend	$0.324 ( 2023-06-02 )
Next Dividend	$0 ( N/A )
P/E	14.96
ATR14	$0 (0.00%)

Ipsen S.A. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Ipsen S.A. Økonomi

Annual	2023
Omsetning:	$3.13B
Bruttogevinst:	$2.35B (75.10 %)
EPS:	$7.79

FY	2023
Omsetning:	$3.13B
Bruttogevinst:	$2.35B (75.10 %)
EPS:	$7.79

FY	2022
Omsetning:	$3.16B
Bruttogevinst:	$2.63B (83.28 %)
EPS:	$1.970

FY	2021
Omsetning:	$3.00B
Bruttogevinst:	$2.46B (82.06 %)
EPS:	$1.948

Financial Reports:

No articles found.

Ipsen S.A. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.324 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Ipsen S.A. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.15 - Stable (22.93%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.262	2013-06-11
Last Dividend	$0.324	2023-06-02
Next Dividend	$0	N/A
Payout Date	2023-06-27
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$3.05	--
Avg. Dividend % Per Year	0.00%	--
Score	3.56	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.15
Div. Directional Score	9.82	--

Next Divdend (Est)
(2025-03-31)

$0.339 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.56

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
YATRF	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
MONDY	Ex Dividend Knight	2023-08-24	Semi-Annually	0.00%
CNLTP	Ex Dividend Knight	2023-07-07	Quarterly	0.00%
STBI	Ex Dividend Knight	2023-08-14	Quarterly	0.00%
HKXCY	Ex Dividend Knight	2023-08-28	Semi-Annually	0.00%
ASBFY	Ex Dividend Knight	2023-06-01	Annually	0.00%
OLCLF	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
DELKY	Ex Dividend Knight	2023-09-01	Quarterly	0.00%
TRBK	Ex Dividend Junior	2023-08-03	Semi-Annually	0.00%
ITJTY	Ex Dividend Junior	2023-10-31	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.206	1.500	5.88	8.82	[0 - 0.5]
returnOnAssetsTTM	0.102	1.200	6.60	7.92	[0 - 0.3]
returnOnEquityTTM	0.178	1.500	9.13	10.00	[0.1 - 1]
payoutRatioTTM	0.155	-1.000	8.45	-8.45	[0 - 1]
currentRatioTTM	1.167	0.800	9.17	7.33	[1 - 3]
quickRatioTTM	0.864	0.800	9.63	7.70	[0.8 - 2.5]
cashRatioTTM	0.325	1.500	9.31	10.00	[0.2 - 2]
debtRatioTTM	0.0626	-1.500	8.96	-10.00	[0 - 0.6]
interestCoverageTTM	37.44	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	10.20	2.00	6.60	10.00	[0 - 30]
freeCashFlowPerShareTTM	7.99	2.00	6.00	10.00	[0 - 20]
debtEquityRatioTTM	0.103	-1.500	9.59	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.817	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.314	1.000	5.73	5.73	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.13	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.495	0.800	-0.0358	-0.0286	[0.5 - 2]
Total Score				13.49

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	3.63	1.000	9.73	0	[1 - 100]
returnOnEquityTTM	0.178	2.50	9.44	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	7.99	2.00	7.34	10.00	[0 - 30]
dividendYielPercentageTTM	1.145	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.20	2.00	6.60	10.00	[0 - 30]
payoutRatioTTM	0.155	1.500	8.45	-8.45	[0 - 1]
pegRatioTTM	0.0973	1.500	-2.68	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.270	1.000	5.76	0	[0.1 - 0.5]
Total Score				6.15

Ipsen S.A.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.